Lilly to submit obesity pill after hitting goal in third late-stage trial
In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.
Previous Post
Therapies to Preserve Function and Quality of Life
Next Post
Portable Imaging and Radiology: Where Things Stand with Point-of-Care Diagnostics
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago